Genotoxicity and antigenotoxicity studies of (traditional medicinal) plants are important from a risk assessment point of view and in the search for new medication against, for example, cancer. It is clear yet that attention should be paid to a number of aspects that may influence the outcome of a study and to which often no or insufficient attention is paid. A short overview is given of such aspects that deserve more attention.
Traditional medicinal plants are used for long periods of time and are, also for this reason, often assumed to be safe. However, this is not always the case [1, 2] . Acute toxicity as a result of usage of medicinal plant extracts is more common than often assumed. It is for example estimated that between 8000 and 20000 annual deaths are recorded in South Africa due to incorrect use of medicinal plants [3] . Also, the FDA believes that serious and moderate or mild adverse events from dietary supplements, including many botanicals and other traditional medicinal products, are significantly underreported and that the annual number of such events is at least 50000 per year [4] . Furthermore, research has shown that a lot of plants which are used either as food ingredients or in traditional medicine can not only be toxic [2] but also mutagenic [2, [5] [6] [7] or even carcinogenic [2, 8] . Genotoxicity tests are being performed in many laboratories worldwide for the sake of awareness of potential hazards and the fact that most traditional medicinal plants have never been the subject of exhaustive (geno)toxicological tests such as is required for modern pharmaceutical compounds. Presence of mutagenic compounds in plant extracts raises concern about the carcinogenic hazards resulting from the long-term use of the plants as medicines or food. Plants with clear mutagenic properties should be considered potentially unsafe. Hence, genotoxicity studies should allow identification of potential dangerous plants and indicate the need for further studies and a warning that (genotoxic) plants should at least be used with caution.
On the other hand, it may be assumed that plants with obvious antimutagenic potential are interesting for their chemo-preventive properties and potential therapeutic use. Antimutagens are chemical agents that reduce or counteract the mutagenicity of physical and chemical mutagens, either by inactivating the mutagen or by preventing the reaction between a mutagen and DNA [9] [10] . The investigation of antigenotoxic properties should be seen in the light of the continuing search for new anti-cancer drugs which is needed because our current anti-cancer drugs often have severe side-effects and replacement by at least as accurate but less hazardous substances is desired. Furthermore, the drugs we use may in the long run also lose their power and efficiency and hence new medication then becomes mandatory. Since mutagens are involved in the initiation and promotion of cancer, research focusing on the identification of novel bioactive phytocompounds that counteract mutagenesis has gained credence in recent years [11] [12] . Because many carcinogens are also genotoxic it may be anticipated that strong anti-genotoxic compounds may be potential anticarcinogens. This explains the search for antigenotoxic properties of plant extracts, and the identification of the compounds from them that are responsible for this property. Such compounds may then be the basis of new anti-cancer drugs or functional food products [7] .
In Europe chemical agents are tested for genotoxicity/mutagenicity according to well described strategies which consists in performing in vitro tests first (e.g., Ames assay, Hprt or mouse lymphoma tests as tests for gene mutations, and in vitro micronucleus or metaphase tests to test for chromosome aberrations). In the case of one or more 'positive' responses, also in vivo tests such as the UDS test, transgenic mouse test, in vivo comet, micronucleus or chromosome aberration tests should be conducted. The results of these will indicate whether or not further two-year carcinogenicity and germ cell mutagenicity tests are required.
The European Medicines Agency has issued its own 'Guideline on the assessment of genotoxicity of herbal substances and preparations', which is issued by the 'Committee on herbal medicinal products' [13] , whereas the 'International Conference on Harmonisation (ICH) of technical requirements for registration of Pharmaceuticals for Human use' issued a 'Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use' [14] [15] .
Contrary to such well-described and accepted strategies, it appears from scientific publications that studies on the genotoxicity and/or antigenotoxicity of traditional medicinal plants on which further in depth investigations are based are often very diverse and do not follow well established protocols or are not conducted according to well described and accepted guidelines. Often, reports on the mutagenicity/genotoxicity of traditional medicinal plants comprise only data from the bacterial Ames assay, or from the Ames test and one or a few other in vitro studies. The Ames test is then conducted in one or a few Salmonella strains and sometimes only in the absence of a metabolizing S9 fraction. The test is used by most laboratories involved in testing genotoxicity/antigenotoxicity of plant extracts for the obvious reason that it is a quite accessible, not Verschaeve very time consuming, and inexpensive test which is furthermore often considered the 'gold standard' in mutation research [16] . However, how reliable has been this approach so far, how efficient in finding a new lead compound against cancer if no complementary or additional studies are performed? This question can be raised because the research often does not take into account a number of aspects that should theoretically be known but that are conveniently not often investigated. The following aspects should particularly be highlighted.
(1) Against which mutagen(s) should we test antimutagenic or antigenotoxic properties?
To determine whether plant extracts (fractions or constituents of them) have antimutagenic/antigenotoxic properties, either bacteria, cells or organisms are exposed to well-known mutagens alone and to the mutagens in combination with the plant material. An extract is antimutagenic when it considerably lowers the effect of the mutagen. Antimutagenicity is then typically expressed as percent inhibition of mutagenicity induced by that mutagen [17] .
It is clear that there are many mutagens acting through different mechanisms. We cannot study them all and a choice should be made. In some investigations a relatively high number of direct acting and indirect acting mutagens were considered (e.g., [18] ) but a rapid literature search reveals that the antimutagenic properties of plant extracts are very often studied against one or two well-known mutagens only. An often used mutagen is 4-nitroquinoline 1-oxide (4-NQO), which is a direct acting mutagen that is for example mutagenic in the Ames test without the requirement of S9mix. In bacteria and yeast, 4-NQO has been shown to be a base substitution mutagen acting at G residues inducing mainly G to A transitions [19] . The carcinogenic action of 4-NQO is thought to be initiated by the enzymatic reduction of its nitro group and formation of 4hydroxyaminoquinoline 1-oxide (4-HAQO) which forms 8hydroxydeoxyguanosine (8OHdG) oxidative damage [20] [21] . Using a direct acting mutagen in antimutagenicity studies is convenient as it avoids the purchase of S9mix to simulate mammalian metabolism and which is, at least for some laboratories, not that easily obtained or affordable. However, is 4-NQO investigated in a bacterial system only an adequate choice? There are other mechanisms of mutation that may be more important in terms of human cancer and chemoprevention. Don't we need to investigate antimutagenesis against at least a number of well-chosen direct and indirect acting mutagens rather than to pick out one that is chosen only because of availability and simplicity? Don't we need to confirm the outcome of a study in bacteria with additional investigations in mammalian/human cell systems?
Some plant extracts also potentiate the genotoxicity of a known mutagen. This means that these extracts are potentially dangerous as they appear to be co-mutagenic and therefore possibly also cocarcinogenic. An extract can be antimutagenic with respect to a known mutagen but this certainly does not imply that it is also antimutagenic when another mutagen is concerned. Furthermore, it is also possible that the same extract is co-mutagenic when administered in conjunction with this second or another mutagen. Thus, an extract can show both mutagenicity and antimutagenicity (they are called 'Janus' mutagens/carcinogens; [22] [23] ). We obviously cannot test co-exposures with all known mutagens. How important are such studies then as the outcome may depend on the chosen mutagen and/or the chosen test system? Many chemicals that are mutagenic/carcinogenic in one tissue type can also have antimutagenic/anticarcinogenic effects in another tissue type. The same holds true for applied doses that can give an apparently contradictory outcome. All this complicates the research and it may be questioned whether we should not design a common strategy to cope maximally with this problem. Such a strategy could imply the use of a limited but deliberate list of different mutagens rather than a random chosen mutagen and should define criteria to help in the decision whether observed antimutagenic properties are sufficiently convincing to justify further work, e.g., bioassay-guided fractionation aimed at identifying lead-compounds for the development of cancer chemotherapeutic agents. A criterion could be a certain minimal percentage of inhibition of mutagenicity (let's say 70%) in at least one bacterial and one mammalian test system, to name only this.
(2) What about false positive results?
In vitro genotoxicity studies have a high sensitivity and thus a low false negative outcome. On the other hand they have a relatively low specificity and hence they give a high rate of false and misleading positive results. The high percentage of false positives is problematic because this implies that in most regulatory frameworks follow-up with in vivo test systems is required, whereas this would not have been necessary when the in vitro tests had given the correct negative results. This is also a great problem with respect to cosmetic products or their ingredients that, according to an EU regulation (1223/2009) which came into force in July 2013, may not be tested on animals anymore, irrespective of the availability of alternative non-animal tests. Conclusions on genotoxicity thus depend on in vitro genotoxicity tests only, and hence a number of alternative in vitro tests are now being investigated in order to obtain a more reliable risk estimate [24] [25] .
The high number of false positive responses from in vitro genotoxicity tests was never considered when mutagenicity or antimutagenicity of medicinal plants was studied. When testing plant extracts in an in vitro mutagenicity test a false positive response has the same consequences, namely an unjustified suspicion of a potential hazard and a demand for additional investigations. However, what about antimutagenicity? An extract that is found to be antimutagenic is considered worthwhile to be further investigated by fractionation and by testing the fractions in a great number of studies up to the identification of the most promising antimutagenic compound. But how sure are we that an extract really possesses the required antimutagenic properties or that absence of antimutagenicity is real? What about false 'positive' responses here? Are they frequent? Don't we need at least a number of repeat and confirmatory experiments to be sure, so as to avoid time consuming and maybe useless follow-up studies? Most published studies were performed only once, sometimes only in the Ames test and no confirmatory studies were conducted, for example in another test system. Should such confirmatory studies not be recommended and considered indispensable before a study can, for example, be accepted for publication in a peer reviewed scientific journal? Shouldn't we need to work out a strategy to overcome and better control this problem?
(3) Histidine content of plants
The Ames assay is often the first, and sometimes only, test that is used to identify mutagenic and antimutagenic plant extracts. This test is adequate of course but may yet constitute a problem in the sense that it is performed on histidine deficient Salmonella strains and that a reverse mutation in the histidine biosynthesis pathway is key to mutagen detection. However, histidine is required for plant growth and development [26] [27] and as a result many plants (and their extracts) do contain high levels of histidine. Petri dishes with Ames test bacteria to which plant extracts are added then have a higher histidine content than control cultures where only trace amounts of histidine are added to allow limited bacterial growth and possibly the expression of His - His + reverse mutations. As a result, bacteria treated with plant-extracts can grow for a longer period in histidine-poor media and colonies may form that are not due to histidine reverse mutations but only to the longer accessibility to histidine that keeps them alive and permits their growth. This may be the reason for false evaluations with respect to mutagenicity as well as antimutagenicity. Should we then not need to measure the histidine content of tested plant extract so as to better evaluate a positive outcome of an Ames test? (4) Antibacterial properties of plants Many plants have antibacterial properties. This means that investigations of mutagenicity and/or antimutagenicity in an Ames assay should also take this into account [28] . We may, for example, find that a given plant extract has a dose-dependent inhibitory effect towards the mutagenicity of a given chemical mutagen. However, was this really due to antimutagenicity, or was it rather due to the antibacterial activity which killed a certain percentage of bacteria in a dose-dependent way? This test compound dependent toxicity can at least partially be controlled by looking at the background layer of bacteria (as should actually be the case in any Ames test), but this is not always done, at least when judging from the great number of published papers. Sometimes equivalent toxicity tests accompanied the Ames assay but they only give indirect evidence of absence of antibacterial activities and no certainty whatsoever. Shouldn't it be mandatory to accompany any study in bacteria on mutagenicity and/or antimutagenicity of plant extracts with a study on their antibacterial activity? Such a test is apparently not difficult to conduct, and is quite rapid and efficient [29] . . (5) Shouldn't we replace antimutagenicity studies by alternative but more informative investigations?
It should be clear from the above considerations that studies on mutagenic and antimutagenic properties of (medicinal) plant extracts are complex and that no single study can provide sufficient information on which further investigations can be based. One may wonder whether such studies should not preferentially be replaced by another approach which is possibly less cumbersome and more advisable. As a possible example, one may cite the evaluation of the antioxidant capacity of medicinal plants. It is known that many of these plants have strong antioxidant properties, as is the case with many anticarcinogens. Hence, if it could be proven that strong antioxidants are most often also strong antimutagens, the testing of the antioxidant capacity of an extract may be a good alternative for the identification of anticarcinogens [28] . This is however far from proven and is only given as an example of a potentially interesting alternative approach.
(6) Plants may have different properties according to the location where they grow
Another aspect of concern may be that identical plants may have different properties according to the location where they grow. This is because they are subject to different environmental conditions and hence behave differently according to the external stimuli they receive. As an example we can cite Rotheca myricoides, which possesses strong antimutagenic properties, at least according to one of our investigations [7] . However, this could apparently not be confirmed by another independent investigation (E. Elgorashie, personal communication). An explanation is that the plants were collected in another season and in places that were quite distant from each other and therefore provided different environmental conditions. These differences may account for differences in biological response.
Different conditions may also be the result of environmental contaminations that play an important role in determining plant behavior. For example, plants may be contaminated with hazardous substances such as toxic metals, agrochemicals and pathogenic microorganisms [30] . This is possible when plants are harvested in polluted regions but also when plants are used that are bought on the street. It is indeed common practice that many traders, for example in Africa, simply trade their goods from the pavements or bare surfaces adjacent to busy roads or in the city center near places where commuters catch taxis or buses [31] . Therefore, contamination by atmospheric deposits from urban pollution, but also by unfavorable hygienic conditions is not uncommon. Where harvesting of plant materials for medicinal use was formerly made by trained traditional health practitioners known for their excellent skills as herbalists, recent urbanization and increasing demands has led to increasing harvesting and trade by untrained and less scrupulous commercial gatherers [32] [33] .
Contamination of medicinal plants is thus becoming a major concern in traditional medicine. The uptake and accumulation of toxic metals provide one important example as it is known that this may result in numerous physiological changes that may include, amongst others, inactivation of certain enzymes and blocking functional groups of metabolically important molecules [31] . Physiological changes due to different environmental stimuli may result in different mutagenic and/or antimutagenic properties.
(7) Considering plant metabolism
This brings us to another aspect that is worth considering, even though probably less important with respect to antimutagenicity studies aimed at identifying anticarcinogens. It is known that smoke or smoke compounds may stimulate seed germination and that they also can enhance seedling vigor and promote plant growth. Treating plants or seeds with smoke, smoke water or some of its active components may also result in an increase in the number of marketable fruits. Nowadays, "smoke technology" is currently used as a germination stimulant to aid the re-vegetation of mined areas, such as at bauxite mines in Western Australia [34] [35] or to promote the germination of many indigenous fynbos species for horticultural purposes. However, especially if smoke compounds were to be used as fertilizers and for agricultural purposes it is necessary to be sure that the treatment is not potentially harmful. For this purpose we already investigated whether smoke water or isolated 'smoke compounds' are mutagenic and/or alter antimutagenic properties. So far we have not found any indication of genotoxicity using different in vitro mutagenicity tests or indicator tests, both in the presence and absence of S9 [36] [37] [38] . However, it may not be sufficient to test the genotoxic properties of the smoke or smoke compounds because smoke-treated plants may transform smoke-compounds into dangerous substances by their plant metabolic system. It is known that metabolic microsome preparations from plants have similarities but also dissimilarities with those from mammals, and hence plant specific biotransformation systems should also be used in mutagenicity tests, if appropriate. This was not yet done in our previous investigations where only S9 from Arochlor treated rats was added to simulate mammalian metabolism but not plant metabolism. Metabolic microsome preparations can be obtained from different plants. A Tradescantia S9 fraction was already used by Scott et al. in 1978 [39] , whereas Trenck and Sandermann [40] Verschaeve used microsome fractions from pea and soybean. Higashi et al. [41] used S9 from Jerusalem artichoke and Takehisa and Kanaya [42] described a so-called S10 fraction that was prepared from Vicia faba. So far there are only a limited number of investigations where plant microsomes, S10 or alternative plant biotransformation systems were used. Maybe this should be considered in future studies where plant metabolism is important.
Conclusion:
Mutagenicity and antimutagenicity studies of (traditional medicinal) plants is important from a risk assessment point of view and in the search for new medication against, e.g., cancer. However, one may wonder how many plant derived compounds that are now major ingredients in our medicines against cancer (for example, taxol and vinblastine) would have been identified based on an antigenotoxicity testing procedure that is followed at the present time? Many anticancer drugs are, furthermore, aneugens that cannot be detected in bacterial test systems as they lack a mitotic spindle apparatus that is present in mammalian/human cells. In other words, don't we need a more rigorous testing protocol or should this kind of studies not be conducted with respect to minimal requirements to enhance the probability of finding lead-compounds for the development of cancer chemotherapeutic agents? It is clear that attention should be paid to a number of aspects that may influence the outcome of a study and to which often no or insufficient attention is paid. We have given a short overview of such aspects that deserve more attention than is the case at present.
